索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]郭晨媛,李福,杨五小.心力衰竭恶化的研究进展[J].国际心血管病杂志,2024,04:193-196.
点击复制

心力衰竭恶化的研究进展(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2024年04期
页码:
193-196
栏目:
综述
出版日期:
2024-07-31

文章信息/Info

Title:
-
作者:
郭晨媛; 李福; 杨五小
作者单位：030012 太原，山西医科大学第五临床医学院心内科（郭晨媛，杨五小），普外科（李福）
Author(s):
-
关键词:
心衰恶化; 慢性心衰; 维立西呱
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2024.04.001
文献标识码:
-
摘要:
慢性心力衰竭（心衰）是多种心血管疾病的终末阶段，经过积极的治疗，其临床症状会处于稳定状态。心衰恶化是心衰病情进展中的特殊阶段，常伴有症状和体征的进展，往往需要进一步的治疗。目前，心衰恶化并没有明确的诊断标准，且这一阶段标志着患者的预后欠佳且住院次数增加。积极干预此过程，可以显著延缓心衰的进展，改善患者生活质量，减轻家庭及社会负担。该文介绍心衰恶化的定义、早期预测和治疗。
Abstract:
-

参考文献/References

[1] Shakoor A, Abou Kamar S, Malgie J, et al. The different risk of new-onset, chronic, worsening, and advanced heart failure: a systematic review and meta-regression analysis[J]. Eur J Heart Fail, 2024, 26(2):216-229.
[2] Savarese G, Becher PM, Lund LH, et al. Global burden of heart failure: a comprehensive and updated review of epidemiology[J]. Cardiovasc Res, 2023, 118(17):3272-3287.
[3] Butler J, Yang M, Manzi MA, et al. Clinical course of patients with worsening heart failure with reduced ejection fraction[J]. J Am Coll Cardiol, 2019, 73(8):935-944.
[4] Metra M, Tomasoni D, Adamo M, et al. Worsening of chronic heart failure: definition, epidemiology, management and prevention. A clinical consensus statement by the Heart Failure Association of the European Society of Cardiology[J]. Eur J Heart Fail, 2023, 25(6):776-791.
[5] 张健, 张宇辉, 周蕾. 国家心衰指南2023（精简版）[J]. 中国循环杂志, 2023, 38(12):1207-1238.
[6] Greene SJ, Triana TS, Ionescu-Ittu R, et al. Patients hospitalized for De Novo versus worsening chronic heart failure in the United States[J]. J Am Coll Cardiol, 2021, 77(7):1023-1025.
[7] Girerd N, Seronde MF, Coiro S, et al. Integrative assessment of congestion in heart failure throughout the patient journey[J]. JACC Heart Fail, 2018, 6(4):273-285.
[8] 叶绍东, 黎励文, 蔺亚晖, 等. 规范应用心肌肌钙蛋白和利钠肽现场快速检测专家共识（2020年）[J]. 中国循环杂志, 2020, 35(11):1045-1051.
[9] McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure[J]. Eur Heart J, 2021, 42(36):3599-3726.
[10] Florkowski C, Don-Wauchope A, Gimenez N, et al. Point-of-care testing (POCT) and evidence-based laboratory medicine (EBLM)-does it leverage any advantage in clinical decision making?[J]. Crit Rev Clin Lab Sci, 2017, 54(7/8):471-494.
[11] Ishii J, Nomura M, Nakamura Y, et al. Risk stratification using a combination of cardiac troponin T and brain natriuretic peptide in patients hospitalized for worsening chronic heart failure[J]. Am J Cardiol, 2002, 89(6):691-695.
[12] D’Aloia A, Faggiano P, Aurigemma G, et al. Serum levels of carbohydrate antigen 125 in patients with chronic heart failure: relation to clinical severity, hemodynamic and Doppler echocardiographic abnormalities, and short-term prognosis[J]. J Am Coll Cardiol, 2003, 41(10):1805-1811.
[13] Ordu S, Ozhan HK, Alemdar R, et al. Carbohydrate antigen-125 and N-terminal pro-brain natriuretic peptide levels: compared in heart-failure prognostication[J]. Tex Heart Inst J, 2012, 39(1):30-35.
[14] Davison BA, Senger S, Sama IE, et al. Is acute heart failure a distinctive disorder? An analysis from BIOSTAT-CHF[J]. Eur J Heart Fail, 2021, 23(1):43-57.
[15] Emdin M, Aimo A, Vergaro G, et al. sST2 predicts outcome in chronic heart failure beyond NT-proBNP and high-sensitivity troponin T[J]. J Am Coll Cardiol, 2018, 72(19):2309-2320.
[16] Aimo A, Vergaro G, Ripoli A, et al. Meta-analysis of soluble suppression of tumorigenicity-2 and prognosis in acute heart failure[J]. JACC Heart Fail, 2017, 5(4):287-296.
[17] Boorsma EM, Ter Maaten JM, Damman K, et al. Albuminuria as a marker of systemic congestion in patients with heart failure[J]. Eur Heart J, 2023, 44(5):368-380.
[18] Ren L, Li FJ, Tan X, et al. Abnormal plasma ceramides refine high-risk patients with worsening heart failure[J]. Front Cardiovasc Med, 2023, 10:1185595.
[19] Pellicori P, Platz E, Dauw J, et al. Ultrasound imaging of congestion in heart failure: examinations beyond the heart[J]. Eur J Heart Fail, 2021, 23(5):703-712.
[20] Zito A, Princi G, Romiti GF, et al. Device-based remote monitoring strategies for congestion-guided management of patients with heart failure: a systematic review and meta-analysis[J]. Eur J Heart Fail, 2022, 24(12):2333-2341.
[21] 葛均波, 霍勇, 杨杰孚, 等. 慢性心衰“新四联”药物治疗临床决策路径专家共识[J]. 中国循环杂志, 2022, 37(8):769-781.
[22] Girerd N, Mewton N, Tartière JM, et al. Practical outpatient management of worsening chronic heart failure[J]. Eur J Heart Fail, 2022, 24(5):750-761.
[23] Cox ZL, Hung R, Lenihan DJ, et al. Diuretic strategies for loop diuretic resistance in acute heart failure: the 3T trial[J]. JACC Heart Fail, 2020, 8(3):157-168.
[24] Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in patients with heart failure and reduced ejection fraction[J]. N Engl J Med, 2020, 382(20):1883-1893.
[25] Varela-Chinchilla CD, Sánchez-Mejía DE, Trinidad-Calderón PA. Congenital heart disease: the state-of-the-art on its pharmacological therapeutics[J]. J Cardiovasc Dev Dis, 2022, 9(7):201.
[26] Gheorghiade M, Greene SJ, Butler J, et al. Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: the SOCRATES-REDUCED randomized trial[J]. JAMA, 2015, 314(21):2251-2262.
[27] Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in patients with heart failure and reduced ejection fraction[J]. N Engl J Med, 2020, 382(20):1883-1893.
[28] Sj G, B J, Jj B, et al. Management of worsening heart failure with reduced ejection fraction: JACC focus seminar 3/3[J]. J Am Coll Cardiol, 2023, 82(6):559-571.
[29] Greene SJ, Bauersachs J, Brugts JJ, et al. Worsening heart failure:nomenclature, epidemiology, and future directions: JACC review topic of the week[J]. J Am Coll Cardiol, 2023, 81(4):413-424.

备注/Memo

备注/Memo:
基金项目：山西省科技厅自然科学研究面上基金（202103021224373）通信作者：杨五小， E-mail：65987026@qq.com
更新日期/Last Update: 2024-07-31